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We report a constellation of cervical polyneuropathies in a patient treated with concurrent bortezomib, cetuximab, and cisplatin
alongside intensitymodulated radiotherapy for carcinoma of the tonsil with neckmetastasis.The described deficits include brachial
plexopathy, cervical sensory neuropathy, and oculosympathetic, recurrent laryngeal, and phrenic nerve palsies within the ipsilateral
radiation field. Radiation neuropathy involving the brachial plexus is typically associated with treatment of breast or lung cancer;
however, increased awareness of this entity in the context of investigational agents with potential neuropathic effects in head and
neck cancer has recently emerged. With this report, we highlight radiation neuropathy in the setting of investigational therapy for
head and neck cancer, particularly since these sequelae may present years after therapy and entail significant and often irreversible
morbidity.
1. Introduction
We report the case of a patient with head and neck cancer
(HNC)who developedmultiple distinct neuropathies follow-
ing participation in a clinical trial in which she received con-
current bortezomib, cetuximab, cisplatin, and radiotherapy.
The patient’s neuropathies include brachial plexopathy, cervi-
cal allodynia, and oculosympathetic, recurrent laryngeal, and
phrenic nerve palsies. This is the first case to describe such
an array of deficits in the context of this particular treatment
regimen.
Radiation-induced brachial plexopathy (RIBP) has long
been recognized as a potential toxicity of radiation therapy
in patients with carcinoma of the breast or lung. There is
emerging recognition of the potential for RIBP in patients
treated for HNC.
2. Case Presentation
A 54-year-old female presented to her primary care provider
with a one-month history of a lateral neck mass and con-
current pooling of salivary secretions. The patient reported
current alcohol and tobacco usage with approximately 40-
pack-year history. Her past medical history included chronic
hepatitis C infection. Persistence of the neck mass despite
antibiotic therapy prompted referral to an otolaryngologist
whereupon the patient was noted to have an ulcerative
lesion of the left palatine tonsil in addition to a left cervi-
cal mass measuring 2 × 3 cm. Fine needle aspiration and
pathologic analysis of the cervical mass revealed squamous
cell carcinoma (SCCa) positive for human papilloma virus.
Two months after initial symptom onset, positron emis-
sion tomography/computed tomography revealed increased
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Figure 1: (a) Composite plan with coronal isodose distributions. (b) MRI of the brachial plexus, with T2 prolongation on the left (arrow).
Cranial and brachial nerve roots emerge in isodose regions receiving 6600–7400 cGy.
uptake in the left tonsillar region with a standardized uptake
value (SUV) of 15.2 along with uptake in a left level II cervical
lymph node with a SUV of 11.9. The patient was subsequently
referred to the National Institutes of Health and diagnosed
with a T1N2bM0, stage IVA SCCa of the oropharynx with
primary site in the left palatine tonsil. In the time leading
up to referral, the patient noted dysphagia, odynophagia, and
intermittent otalgia. Physical examination was significant for
an enlarged and erythematous left palatine tonsil that was
firm to palpation in addition to left-sided jugulodigastric
lymphadenopathy measuring 3.5 × 3 cm.
Following direct laryngoscopy with biopsy of the left
tonsil, the patient was enrolled inNCI-7893, an IRB approved
Phase I dose escalation study of bortezomib, cetuximab, and
Intensity Modulated Radiation Therapy (IMRT) [1]. Borte-
zomib (1.3mg/m2) was given intravenously twice weekly
on days 1, 4, 8, and 11, every 21 days. Bortezomib and
cetuximab 400mg/m2 were started one week before com-
bining bortezomib and weekly cetuximab 250mg/m2 with
IMRT. However, during the first five weeks of treatment, the
patient developed repeated infusion reactions to cetuximab
despite reduced infusion rates and administration of anti-
histamine medication and steroids. No reduction in the left
neck adenopathy was observed. It was therefore elected to
remove the patient from the research protocol; her treatment
regimen was transitioned to include a standard dose of
cisplatin (100mg/m2) during completion of the last 3weeks of
radiation therapy. The patient’s planned radiation therapy of
70 Gray (Gy) delivered in daily 2Gy fractions to the primary
tumor and gross nodal disease was boosted to 74Gy. A dose
of 70Gy was delivered in daily 2Gy fractions to the high
risk left neck, and a dose of 54Gy was delivered to the lower
left neck and low risk lymph nodes in the contralateral neck
(Figure 1(a)).
Thirty months after completion of combined chemother-
apy and radiotherapy, the patient developed intermittent
paresthesia of the left hand and aching pain throughout
the entire left upper extremity. On physical examination,
the patient was found to have atrophy of the left forearm
extensor musculature. Weakness was demonstrated with
left shoulder abduction and left elbow, wrist, and finger
extension. Subsequent physiatry assessment demonstrated a
markedly reduced left-sided grip strength of 47 lbf compared
to 58 lbf in the right hand. Electromyography (EMG) showed
sensory nerve abnormalities in the left upper extremity.
Magnetic resonance imaging (MRI) of the left brachial plexus
revealed T2 prolongation within the C7 nerve root indicative
of inflammation and/or edema (Figure 1(b)). The patient
was diagnosed with radiation-induced brachial plexopathy
(RIBP). Initially, the patient reported significant relief of pain
with gabapentin and physical rehabilitation.
Three months after onset of upper extremity symptoms,
the patient developed hoarseness and flexible laryngoscopy
revealed left vocal fold paralysis and a pan-glottic gap with
phonation (Figure 2(b)). The patient was also noted to
have left-sided ptosis and miosis consistent with Horner’s
syndrome. Repeat MRI of the neck showed no evidence
of recurrence and no mass lesions affecting the course of
the left recurrent laryngeal nerve or carotid plexus. The
patient’s hoarseness was not responsive to corticosteroid
administration and she underwent injection laryngoplasty
with improvement in voice quality. The patient’s condition
remained stable until, nearly three years after completion
of concurrent chemoradiotherapy, she began to experience
severe allodynia described as a burning sensation extending
from the left supraclavicular skin towards the left sub-
mandibular region and the superior aspect of the left shoul-
der. This pain was attributed to potential progressive cervical
sensory neuropathies analogous to the patient’s RIBP. Shortly
thereafter, she also began to experience intermittent dyspnea
both at rest and on exertion. Imaging of the chest suggesting
elevation of the left hemidiaphragm and associated atelectasis
(Figure 2(b)) was confirmed by fluoroscopy as consistent with
left phrenic nerve palsy.
At the time of this writing, the patient’s deficits were
stable and/or partially responsive to oral narcotic analgesia
and physical rehabilitation exercises.
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Figure 2: (a) Laryngoscopy photograph of the vocal folds, demonstrating left vocal fold paresis. (b) Portable chest radiograph with elevation
of the left hemidiaphragm (arrow).
3. Discussion
The patient described above, following administration of
three separate therapeutic agents alongside radiation therapy,
experienced brachial plexopathy, cervical nerve irritation,
and oculosympathetic, recurrent laryngeal, and phrenic
nerve palsies in the ipsilateral radiation field.
The pathophysiology of radiation-induced neuropathy
is attributed to fibrosis with entrapment of nerve fibers,
ischemic injury from capillary disruption, demyelination,
and direct axonal damage [2–4]. Onset of radiation neuropa-
thymay occur months to decades after initial therapy and the
deficits are typically irreversible [5].
RIBP is a delayed, progressive potential toxicity associ-
ated with irradiation of the neck and supraclavicular regions;
clinical manifestations include pain, paresthesia, and weak-
ness of the upper extremity [6]. Long recognized in the
context of breast and lung cancers, increased awareness of
RIBP in patients treated for HNC has emerged over the last
five years [7]. A history of irradiation should increase clinical
suspicion of the diagnosis, which may be confirmed via
EMG and/orMRI. Distinction from recurrent malignancy or
alternate primary is an important diagnostic consideration.
A correlation has been shown between total radiation dose,
fraction size, and the particular method by which the region
is irradiated [8, 9]. However, the risk factors and associated
radiation parameters remain poorly defined, particularly in
patients with HNC in which higher doses of radiation are
typically required [10–12].
Chen et al. prospectively screened 330 patients who
completed radiation therapy for HNC using a standardized
questionnaire in order to identify predictors of RIBP [7].
Their study showed that the use of concurrent chemotherapy
increased the risk of developing neuropathy and that delivery
of higher doses of radiation (defined as >70Gy) to the
brachial plexus was strongly associated with subsequent
symptom development. These findings were consistent with
prior recommendations by Emami et al. who postulated that
treatments above 70Gy drastically increased rates of injury
[13]. However, there were a small proportion of patients
in the study that developed symptoms attributable to RIBP
below this dosing threshold indicating that the underlying
mechanism of injury may be multifactorial, including an
increased risk with concurrent chemotherapy highlighted in
the above report.
Vocal fold paralysis (VFP) has also recently been cited
as a delayed complication of radiotherapy for HNC [5].
A case series by Crawley and Sulica identified 10 patients
with VFP attributable to radiation therapy for HNC with
symptom onset ranging from one to 27 years following initial
therapy. None of these patients experienced self-resolution
of VFP. Injection augmentation was shown to be an effective
management option in that case series and as affirmed by the
response demonstrated in the above case report [5].
Phrenic nerve injury secondary to radiation therapy
is rarely described, with only four previously reported
cases. Regarding potential contributions from monoclonal
antibody therapy, one case describes a patient with bilat-
eral phrenic nerve injury secondary to ipilimumab [14].
Though the patient presented in this case report received
a different monoclonal antibody, cetuximab, further study
into potential adverse effects of treatment with monoclonal
antibodies may be warranted. Cetuximab is an inhibitor of
the epidermal growth factor receptor (EGFR). Two-thirds of
patients enrolled in a Phase I study of the EGFR inhibitor
gefitinib in combination with paclitaxel and radiotherapy
were noted to develop severe oral dysesthesia [15]. In that
study, the combination of an EGFR inhibitor appears to have
exacerbated the potential neuropathic effects of paclitaxel
with radiotherapy, since in previous trials of cetuximab in
combination with radiotherapy for HNC, encompassing 227
patients, there were no reported instances of RIBP or other
distinct nerve injuries as described in the present case report
[14–16].
A common dose-limiting toxicity associated with borte-
zomib administration is painful sensory peripheral neuropa-
thy [17, 18], and bortezomib may also have contributed to
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the cervical sensory and other neuropathies in combination
with radiation described in this report.The effectmay be dose
dependent, as this was the only patient receiving 1.3mg/m2
bortezomib, while other patients receiving lower doses in
this and previous studies of bortezomib in combination
with radiotherapy have not shown such limiting neurologic
toxicities [1, 19]. The neuropathies described in this report
cannot be attributed to acute bortezomib toxicity given that
bortezomib-induced neuropathy typically manifests during
the treatment course and has been shown to be reversible
[19, 20].Therefore, the sequelae exhibited in the above patient
may indicate that the neurotoxicity of bortezomib poten-
tiates, or is potentiated by, concurrent radiotherapy and/or
EGFR inhibition. Cisplatin chemotherapy is also reported to
cause peripheral sensory neuropathies [21–23]. A significant
portion of the left neck received a dose of 70Gy or higher due
to hot spots in the composite treatment plans. The majority
of the brachial plexus received less than 70Gy; however, the
patient’s radiation exposure seems likely to have sensitized
nearby nervous structures to the toxic effects of bortezomib,
cetuximab, and cisplatin, given the polyneuropathic effects
within the radiation field.
There exists the potential of an immune-mediated com-
ponent to the described nerve injuries. One case report
describes a chronic immune-mediated polyneuropathy five
months following cetuximab administration for treatment
of HNC [17]. EGFR inhibition has been shown to increase
expression of proinflammatory genes including interleukin-
6 (IL-6) [24]. Interestingly, bortezomib-induced neuropathy
is associated with relative increases in the number ofTh2 cells
and IL-6 levels [25].
4. Conclusion
The above case report demonstrates that concurrent admin-
istration of bortezomib in conjunction with cetuximab and
radiotherapy is associated with an array of distinct cervical
neuropathies. Radiation-induced nerve injuries, including
RIBP, are an important and potentially underrecognized
consideration inmonitoring of patients treated for HNC.The
clinician monitoring patients following chemoradiotherapy
for HNC must be attuned to potential nerve injuries given
the sometimes decades long latency to symptom onset,
the significant impairment these toxicities entail, and their
irreversible nature.
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